Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias?

Collider Bias Is Only a Partial Explanation for the Obesity Paradox

(2016) Matthew Sperrin et al.   EPIDEMIOLOGY

Should Patients with Chronic Disease Be Told to Gain Weight? The Obesity Paradox and Selection Bias

(2015) Martín Lajous et al.   AMERICAN JOURNAL OF MEDICINE

Incident Pneumonia and Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Double Effect of Inhaled Corticosteroids?

(2015) Emir Festic et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Does selection bias explain the obesity paradox among individuals with cardiovascular disease?

(2015) Hailey R. Banack et al.   ANNALS OF EPIDEMIOLOGY

Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis

(2015) Emir Festic et al.   COPD-Journal of Chronic Obstructive Pulmonary Disease

Inhaled corticosteroids in COPD: the clinical evidence

(2014) Pierre Ernst et al.   EUROPEAN RESPIRATORY JOURNAL

Risk factors for community-acquired pneumonia in adults in Europe: a literature review

(2013) Antoni Torres et al.   THORAX

Inhaled corticosteroids in COPD and the risk of serious pneumonia

(2013) Samy Suissa et al.   THORAX

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials

(2013) Mark T Dransfield et al.   Lancet Respiratory Medicine

Observational Study of Inhaled Corticosteroids on Outcomes for COPD Patients with Pneumonia

(2011) Dennis Chen et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Reported Pneumonia in Patients With COPD

(2010) Peter M.A. Calverley et al.   CHEST

Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia

(2010) R. Malo de Molina et al.   EUROPEAN RESPIRATORY JOURNAL

Long-term Use of Inhaled Corticosteroids and the Risk of Pneumonia in Chronic Obstructive Pulmonary Disease

(2009) Sonal Singh et al.   ARCHIVES OF INTERNAL MEDICINE

Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes

(2009) Antonio Anzueto et al.   COPD-Journal of Chronic Obstructive Pulmonary Disease

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results

(2009) C. Crim et al.   EUROPEAN RESPIRATORY JOURNAL

Illustrating bias due to conditioning on a collider

(2009) Stephen R Cole et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD

(2009) Min J. Joo et al.   RESPIRATORY MEDICINE

Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease

(2008) M. Bradley Drummond et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of fluticasone propionate/salmeterol (250/50μg) or salmeterol (50μg) on COPD exacerbations

(2008) Gary T. Ferguson et al.   RESPIRATORY MEDICINE

The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide

(2007) Jadwiga A. Wedzicha et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE